• Belinda A Di Bartolo, Daniel J Scherer, and Stephen J Nicholls.
• South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia.
• Arch Med Sci. 2016 Dec 1; 12 (6): 1302-1307.

AbstractIncreasing attention has focused on efforts to promote the biological activities of high-density lipoproteins (HDL) in order to reduce cardiovascular risk. Targeting apolipoprotein A-I (apoA-I), the major protein carried on HDL particles, represents an attractive approach to promoting HDL by virtue of its ability to increase endogenous synthesis of functional HDL particles. A number of pharmacological strategies that target apoA-I, including upregulation of its production with the bromodomain and extraterminal (BET) protein inhibitor RVX-208, development of short peptide sequences that mimic its action, and administration as a component of reconstituted HDL particles, have undergone clinical development. The impact of these approaches on cardiovascular biomarkers will be reviewed.

5 keywords...

hide…